AstraZeneca's antisense therapy "Eplontersen" applies for listing in China
According to the CDE website, AstraZeneca's antisense therapy Eplontersen (IONIS-TTR-LRx, trade name: Wainua) has applied for listing in China for the treatment of hereditary transthyretin-mediated amyloidosis polyneuropathy (ATTRv-PN). ATTRv-PN can lead to peripheral nerve damage and motor disorders within five years of diagnosis, with patients typically dying within ten years if left untreated. It is estimated that there are approximately 300,000 to 500,000 ATTR-CM patients globally, with around 40,000 cases of ATTRv-PN. Public information indicates that Eplontersen (IONIS-TTR-LRx) is a ligand-conjugated antisense oligonucleotide (LICA) drug designed to reduce the production of serum TTR to treat both hereditary and non-hereditary ATTR. The drug was approved for marketing in the United States in December 2023. Under the global development and commercialization agreement between AstraZeneca and Ionis, the two companies will jointly develop and commercialize Eplontersen in the United States, while AstraZeneca will handle the development and commercialization in the rest of the world (excluding Latin America)
According to the information obtained from Zhitong Finance APP, CDE website shows that AstraZeneca (AZN.US) has applied for listing in China for its antisense therapy Eplontersen (IONIS-TTR-LRx, trade name: Wainua), used to treat hereditary transthyretin-mediated amyloidosis polyneuropathy (ATTRv-PN). ATTRv-PN can lead to peripheral nerve damage and motor disorders within five years of diagnosis, with patients typically dying within ten years if left untreated. It is estimated that there are approximately 300,000 to 500,000 ATTR-CM patients globally, with around 40,000 cases of ATTRv-PN.
Public information indicates that Eplontersen (IONIS-TTR-LRx) is a ligand-conjugated antisense oligonucleotide (LICA) drug designed to reduce the production of serum TTR to treat both hereditary and non-hereditary ATTR. The drug was approved for marketing in the United States in December 2023. Under the global development and commercialization agreement reached between AstraZeneca and Ionis, the two companies will jointly develop and commercialize Eplontersen in the United States, while development and commercialization in the rest of the world (excluding Latin America) will be carried out by AstraZeneca